Laurus Labs Stock Shows Signs of Recovery After January 2026 Decline

Laurus Labs Ltd, a pharmaceutical company, experienced a roughly 20% decline from its January 2026 peak of Rs 1,140, reaching Rs 917 by early February. Experts suggest the stock may be bottoming out, recommending high-risk short-term traders consider buying with a target of Rs 1,120 within 2-3 weeks. Additional market tools and expert analyses are available to assist investors in making informed decisions.